ALNY Alnylam Pharmaceuticals
FY2025 10-K
Alnylam Pharmaceuticals (ALNY) filed its fiscal year 2025 10-K annual report with the SEC on Feb 12, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Achieved first profitability in 2025 with net product revenues approx. $3.0B, primarily from TTR franchise growth
- • Initiated Phase 3 trials in 2025 for nucresiran (next-gen TTR silencer) and zilebesiran (hypertension), emphasizing late-stage pipeline expansion
Risk Factors
- • Regulatory risk from U.S. drug price control measures, Medicare/Medicaid reimbursement changes potentially reducing AMVUTTRA net price
- • Geopolitical exposure to foreign currency fluctuations in Japanese yen, Euro, and British pound affecting revenues and expenses
Financial SummaryXBRL
Revenue
$3.7B
Net Income
$314M
Operating Margin
13.5%
Net Margin
8.4%
ROE
39.8%
Total Assets
$5.0B
EPS (Diluted)
$2.33
Operating Cash Flow
$524M
Source: XBRL data from Alnylam Pharmaceuticals FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Alnylam Pharmaceuticals
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.